PR Newswire10.07.20
Eli Lilly and Company and DexCom Inc. began a joint program for U.S. healthcare providers (HCPs) about Lilly's new rapid-acting mealtime insulin Lyumjev (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), now available in U.S. pharmacies, and Dexcom G6 CGM Systems. The program is designed to help clinicians use data to inform diabetes management, including giving visibility to the benefits of a new mealtime insulin.
HCPs treating type 1 and type 2 diabetes will be able to assess their patients' glucose levels and time in range with Dexcom G6 or Dexcom G6 Pro, either in blinded or unblinded mode, helping them quickly identify adult patients who struggle to manage their postprandial glucose (PPG) levels (glucose levels following meals) and who may benefit from a treatment like Lyumjev. As PPG is often overlooked as a significant contributor to A1C,1 this partnership also aims to elevate PPG monitoring as an important component of diabetes treatment management.
"When it comes to treating diabetes, our partnership with Dexcom has the potential to be meaningful for HCPs who want to help their patients who may be struggling to manage their blood glucose levels after meals," said Adrienne Brown, vice president, U.S. Diabetes and Connected Care, Lilly. "Through this program, we can inspire confidence as clinicians and their patients evaluate new treatment options by showcasing how using these resources together can inform diabetes care."
Lilly and Dexcom will enhance HCP education by jointly sharing information about Lyumjev and the Dexcom G6 and G6 Pro through a variety of channels.
"We are thrilled to partner once again with a leader in diabetes care like Lilly," said Rick Doubleday, chief commercial officer at Dexcom. "Our goal is that the real-time data provided through Dexcom G6 and Dexcom G6 Pro will allow healthcare providers to help their patients with diabetes make more informed decisions, measure and evaluate their time in range, and have more visibility to the potential benefits of transitioning to a new mealtime insulin such as Lyumjev."
Those interested in learning more about Dexcom CGM or getting started on the Dexcom G6 should visit Dexcom.com. The Dexcom G6 is covered by 98 percent of private insurance in the U.S., by Medicare and by Medicaid in many states across the country. Dexcom also recently launched a patient assistance program available to current U.S. customers who lost their health insurance coverage due to the impacts of COVID-19.
Lyumjev is a novel formulation of insulin lispro, developed to speed the absorption of insulin into the bloodstream and reduce A1C levels in adults with diabetes. In clinical studies, Lyumjev provided superior reduction in blood sugar spikes compared with Humalog (insulin lispro injection) when blood sugar was measured 1 and 2 hours after a meal. Lyumjev was approved by the FDA on June 15, 2020. HCPs can now prescribe Lyumjev, which is available for pharmacies nationwide to order. People who have commercial insurance can visit www.Lyumjev.com to access the Lyumjev Savings Card. For people without insurance coverage, Lyumjev is also included in the Lilly Insulin Value Program for $35 by calling the Lilly Diabetes Solution Center at (833) 808-1234. Operators at the Solution Center are available Monday through Friday from 8 a.m. to 8 p.m. (ET). Lilly is in discussions with insurance providers to make the new rapid-acting insulin available to as many people as possible.
Reference
1 Hershon, K., Hirsh, B., and Odugbesan, O. Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease. Clinical Diabetes. 2019; 37 (3): 250-269. Available at: https://clinical.diabetesjournals.org/content/37/3/250.article-info
HCPs treating type 1 and type 2 diabetes will be able to assess their patients' glucose levels and time in range with Dexcom G6 or Dexcom G6 Pro, either in blinded or unblinded mode, helping them quickly identify adult patients who struggle to manage their postprandial glucose (PPG) levels (glucose levels following meals) and who may benefit from a treatment like Lyumjev. As PPG is often overlooked as a significant contributor to A1C,1 this partnership also aims to elevate PPG monitoring as an important component of diabetes treatment management.
"When it comes to treating diabetes, our partnership with Dexcom has the potential to be meaningful for HCPs who want to help their patients who may be struggling to manage their blood glucose levels after meals," said Adrienne Brown, vice president, U.S. Diabetes and Connected Care, Lilly. "Through this program, we can inspire confidence as clinicians and their patients evaluate new treatment options by showcasing how using these resources together can inform diabetes care."
Lilly and Dexcom will enhance HCP education by jointly sharing information about Lyumjev and the Dexcom G6 and G6 Pro through a variety of channels.
"We are thrilled to partner once again with a leader in diabetes care like Lilly," said Rick Doubleday, chief commercial officer at Dexcom. "Our goal is that the real-time data provided through Dexcom G6 and Dexcom G6 Pro will allow healthcare providers to help their patients with diabetes make more informed decisions, measure and evaluate their time in range, and have more visibility to the potential benefits of transitioning to a new mealtime insulin such as Lyumjev."
Those interested in learning more about Dexcom CGM or getting started on the Dexcom G6 should visit Dexcom.com. The Dexcom G6 is covered by 98 percent of private insurance in the U.S., by Medicare and by Medicaid in many states across the country. Dexcom also recently launched a patient assistance program available to current U.S. customers who lost their health insurance coverage due to the impacts of COVID-19.
Lyumjev is a novel formulation of insulin lispro, developed to speed the absorption of insulin into the bloodstream and reduce A1C levels in adults with diabetes. In clinical studies, Lyumjev provided superior reduction in blood sugar spikes compared with Humalog (insulin lispro injection) when blood sugar was measured 1 and 2 hours after a meal. Lyumjev was approved by the FDA on June 15, 2020. HCPs can now prescribe Lyumjev, which is available for pharmacies nationwide to order. People who have commercial insurance can visit www.Lyumjev.com to access the Lyumjev Savings Card. For people without insurance coverage, Lyumjev is also included in the Lilly Insulin Value Program for $35 by calling the Lilly Diabetes Solution Center at (833) 808-1234. Operators at the Solution Center are available Monday through Friday from 8 a.m. to 8 p.m. (ET). Lilly is in discussions with insurance providers to make the new rapid-acting insulin available to as many people as possible.
Reference
1 Hershon, K., Hirsh, B., and Odugbesan, O. Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease. Clinical Diabetes. 2019; 37 (3): 250-269. Available at: https://clinical.diabetesjournals.org/content/37/3/250.article-info
